康艾注射液联合化疗治疗晚期非小细胞肺癌的临床观察  

Clinical observation of combined Kangal injection with chemotherapy in the treatment of advanced non-small cell lung cancer

作　　者：李劲松[1] 韩亮[1] 袁保兰[1] 戴秀梅[1] 

机构地区：[1]江苏省徐州市中心医院肿瘤内科,江苏徐州221009

出　　处：《中国中医药咨讯》2011年第10期53-55,共3页

摘　　要：目的：观察康艾注射液联合紫杉醇与顺铂方案（TP方案）治疗晚期非小细胞肺癌的临床疗效。方法：将60例患者随机分为2组各30例，治疗组予康艾注射液联合TP方案化疗；对照组只给予TP方案化疗。均化疗3周期后评价疗效。观察近期疗效、毒副反应、Kamofsky评分、体重变化及细胞免疫功能指标变化。结果：治疗组近期疗效有效率为50．0％，对照组近期疗效有效率为43．3％，疗效未见显著性差异（P〉O．05）；治疗组Ⅲ～IV度中性粒细胞减少发生率低于化疗组（P〈0．05）；治疗组Kamofskv评分改善明显（P〈0．05）；治疗组CD4／CD8及NK阳性细胞率治疗后提高（P〈O．05）。结论：康艾注射液有一定的减毒增效作用，其联合TP方案治疗晚期非小细胞肺癌中性粒细胞减少发生率低，可改善患者一般状况及生活质量，提高患者细胞免疫功能。Objective：To observe the efficacy and adverse reactions of Kangai injection plus paclitaxel and cisplatin in the treatment of advanced non-small-cell lung cancer （NSCLC）. Methods： ： 60 cases with advanced NSCLC were randomly divided into two groups, 30 patients of test group were treated with Kangai injection combined with TP, 30 patients of control group were only treated with TP. The chemotherapy effect, side effects,improvement of the quality of life and cellular immune function indexes variation of two groups were evaluated during and after chemotherapy. Results： Bone marrow suppression of test group was lower than in the control group （P 〈 o. 05）, the quality of life, Karnofsky score, the CD4 / CD8 and NK cell activeness in test group increased, the difference was statistically significant （P 〈 0.05）. Conclusion：Kangai injection combined with TP in the treatment of non-small-cell lung cancer have better efficacy, can effectively reduce toxicity and improve quality of life, improve cellular immune function.

关 键 词：康艾注射液 化学疗法 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]